Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans

Keyphrases

• Glucose-dependent Insulinotropic Polypeptide 100%
• Insulin Secretion 100%
• Glucagon Secretion 100%
• Glucagon 81%
• Blood Glucose 45%
• Glucagon-like 36%
• Type 2 Diabetic Patients 27%
• Glucose Effect 27%
• Insulin 27%
• Type I Diabetes 27%
• Type 1 Diabetes Mellitus (T1DM) 27%
• Hypoglycemia 18%
• Endogenous Glucose Production 18%
• Hyperglycemia 18%
• Insulin Release 18%
• Placebo 18%
• Incretin Hormones 18%
• Insulin Response 9%
• Glucose Disposal 9%
• Intravenous Administration 9%
• Hypoglycemia Risk 9%
• Release Effect 9%
• Randomized Placebo-controlled Trial 9%
• Cognitive Function 9%
• Plasma Concentration 9%
• Glycaemia 9%
• Enteroendocrine Cells 9%
• Bifunctional 9%
• Hyperinsulinemic Hypoglycemia 9%
• Low Blood Glucose 9%
• Intestinal mucosa 9%

Biochemistry, Genetics and Molecular Biology

• Insulin Release 100%
• Glucagon Release 100%
• Gastric Inhibitory Polypeptide 100%
• Glucagon 72%
• Glucose Blood Level 72%
• Glucagon-Like Peptide-1 36%
• Gluconeogenesis 18%
• Incretin 18%
• Hyperglycemia 18%
• Normal Human 18%
• Intestine Mucosa 9%
• Cognition 9%
• Progesterone 9%
• Enteroendocrine Cell 9%
• Population Research 9%
• Blood Level 9%
• Insulin Response 9%